Sanjivani Paranteral Limited Demonstrates Strong Financial Performance in FY26

Sanjivani Paranteral Limited reported robust financial results for FY26, with a significant increase in total income and EBITDA. The company's strategic focus on efficiency and customer-centric operations, alongside its new infusion plant in Pune, strengthens its market presence and positions it for continued growth.

Sanjivani Paranteral Limited, a notable entity in the pharmaceutical manufacturing sector, has disclosed its financial performance for the fourth quarter of FY26, showcasing promising growth across its operations. The company achieved a total income of ₹138.09 million and an EBITDA of ₹21.73 million, reflecting a 15.74% margin.

The company's segment-wise performance highlighted significant contributions from injectables and tablets, with export markets driving revenue upticks. Notably, revenue from injectables grew impressively, contributing over 53% to the overall revenue. Simultaneously, tablet sales witnessed a commendable year-on-year growth, underscoring the demand for Sanjivani's healthcare offerings.

Sanjivani's Chairman & Managing Director, Ashwani Khemka, expressed optimism regarding the year ahead, emphasizing the new IV Fluid Infusion Plant in Pune as a keystone in enhancing manufacturing capabilities. Looking forward, the company aims to leverage this expansion to sustain operational efficiency and explore further growth opportunities in both domestic and international markets.